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Dr Todd Rassmussen (San Antonio, Tex). I thank you for
the opportunity to review this and comment on the paper. I
commend the authors for affording me the manuscript in advance
and I enjoyed reading it and I congratulate the group from UT
Southwestern on yet another clear, concise, neat, and germane
manuscript. It was a good read and a nice presentation.
Because of the late hour, I won’t summarize the whole manu-
script. I do, however, have a couple of specific questions andmaybe
you can clarify for me and the group. One pertains to the baseline
similarity or dissimilarity potentially between the aneurysms com-
pared in each of the three groups. As your group knows and has
recently published, the characteristics of the aortic neck are very
important in EVAR and yet in the manuscript there are no data on
the neck anatomy between the three groups. No comparisons.
There are no lengths. No diameters. No calcification scores. There
is really no characterization of the necks in the three groups. And in
the absence of this information, can the authors really be sure of
that valid comparisons can be made between the three groups or
among the three groups? In other words, were regression rates so
favorable in the Medtronic group because the AneuRx grafts were
placed in aneurysms with longer, less dilated necks, easier aneu-
rysms, so to speak? Was there an incidence of graft migration at 1
year? Was there any incidence of Type I endoleaks in any of the
groups?
The second and third questions really just pertain to clinical
relevance and maybe put you on the spot with regards to your
findings. Help us relate this to our practices. First of all, assuming
these trends hold true in longer follow-up, what is their clinical
relevance, would they impact your selection of grafts in the future?
In other words, would you not use a specific graft because its rate
of regression was 5% or 10% less than another graft at 1 year? Is it
clinically relevant or are we just gilding the lily here?
And then lastly relates to the follow-up, which youmentioned,
can we really make after EVAR—given what several groups around
the country observed the expansion at 2 or 3 years—can we really
make valid comparisons with only a 12-month follow-up? Again, I
commend you on you paper. I think it has a lot of potential and you
did a nice presentation.
Dr Harshal Broker. Thank you for those questions. To
address your first question about the neck anatomy. We found that
there were no differences between the aortic neck except that the
Zenith graft was used in patients with larger necks, since this is the
only graft currently available to treat necks greater than 28 mm;
otherwise, there were no differences between the three groups.
Again it should be noted that even with those who received the
Zenith graft, there were no type I endoleaks and no evidence of
type I endoleaks at 1 year. Furthermore, we found no differences
between the groups with regard to type II endoleaks. So as far as we
can tell, the aneurysm morphology between the three groups was
fairly similar. The overall importance of sac shrinkage is unknown
and how much is enough is uncertain. However, as an implanting
physician, it is comfortable to know that the aneurysm is shrinking
and it also comforts the patient as well. Certainly, it is important to
follow these patients to see if these trends persist.
Unidentified speaker. I have two quick questions. There are
pretty good data showing that volumetric analysis is more sensitive
than actual size. Did you look at any volumetric data? And the
second question, we have reported out of our core lab data that
there is an endoleak influence on the rate of sac either expansion or
regression amongst devices. Did you notice any difference when
you looked at the influence of endoleak on sac regression or
expansion in your study?
Dr Broker. As far as volumetric data, we did not look at that,
but I think we do have the data to go back and look in this definite
option to maybe strengthen the paper. In patients with type II
endoleaks, there was still sac regression but it was significantly less
than in those patients who did not have any endoleak. Because of
the overall small number of patients with type II endoleak, we did
not look at device specific outcomes in this regard.
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